Utilized for benign prostatic hyperplasia to manage urinary flow and support relief from obstructive symptoms.
Mechanism of Action
Alfuzosin selectively blocks alpha-1 adrenergic receptors in the lower urinary tract. This action relaxes the smooth muscle in the bladder neck and prostate, improving urine flow and reducing BPH symptoms.
Route of Administration
Oral
Onset Time
1–2 weeks
Duration
24 hours
Contraindications
Moderate to severe hepatic impairment, Hypersensitivity to alfuzosin, Concurrent use of potent CYP3A inhibitors
Severe Adverse Events
Severe hypotension, Priapism, Angina pectoris — requires immediate medical attention
Information related to Alfuzosin is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
